Date: May 9, 2019 07:15 AM - May 10, 2019 05:00 PM
CE Hours
CE Units
Activity Type
- Knowledge-Based and Application-Based
Target Audience(s)
- Pharmacists
Accreditation(s)
The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Co-Sponsor(s)
Requirements for CE Credit
- Identify appropriate contraception options for patients based on indications, side effects, route of administration, length of use and effectiveness.
Speaker(s)/Author(s)
Jennifer Bain, MD
|
Activity Number
0062-9999-19-099-L01-PCE Hours
- Contrast the pharmacologic features of methadone, buprenorphine, and naltrexone
- Describe the goals of an initial evaluation for patients with opioid use disorder
- Describe factors to consider in treatment planning to determine if Office-Based Opioid Treatment (OBOT) is appropriate for the patient
- Identify ways to train to get a buprenorphine waiver
- Identify where you can refer patients for MAT in your practice area
Speaker(s)/Author(s)
Sarah Bradford, MD
|
Activity Number
0062-9999-19-100-L01-PCE Hours
2. Prescribe appropriate weight loss medications based on the individual patient
3. Advise patients on diet plans based on current evidence
4. Advise patients on exercise goals
5. Incorporate other behavioral strategies into weight management plans
Speaker(s)/Author(s)
Kristen Hood Watson, MD
|
Activity Number
0062-9999-19-101-L01-PCE Hours
- Assess the need for added thyroid hormone lab studies in specific situations
- Recall existing data in treating subclinical hypothyroidism
- Discuss the question of using T3
Speaker(s)/Author(s)
Anita Ramsetty, MD, CCMS
|
Activity Number
0062-9999-19-102-L01-PCE Hours
- Compare benefits and risks of DOACs to standard of care anticoagulation in the treatment of cancerassociated thrombosis
- Identify patients with heparin-induced thrombocytopenia who may be candidates for DOACs
- Recognize patient-specific factors that may compromise safety or effectiveness of DOAC therapy
Speaker(s)/Author(s)
Nicole Bohm, PharmD, BCPS
|
Activity Number
0062-9999-19-103-L01-PCE Hours
- Identify patient-specific risk-enhancing factors that would indicate a patient??s need for statin therapy
- Incorporate the updated goals for LDL-C levels into current practice models
- Utilize non-statin pharmacotherapy options for certain patients
- Examine the supporting evidence responsible for the updated guidelines
Speaker(s)/Author(s)
Michael Corvino, PharmD, CDE
|
Activity Number
0062-9999-19-104-L01-PCE Hours
- Articulate updates in dementia care and research
- Apply current recommendations and evidence in patients at risk of cognitive impairment
Speaker(s)/Author(s)
Russell Blackwelder, MD, MDiv, CMD
|
Activity Number
0062-9999-19-105-L01-PCE Hours
- Describe the new IDSA guidelines regarding treatment of Clostridium difficile colitis
- Compare the antiviral treatment option for influenza
- Compare the treatment modalities for impetigo
Speaker(s)/Author(s)
Lisa Mims, MD, MSCR
|
Activity Number
0062-9999-19-106-L01-PCE Hours
- Compare and contrast the AHA/ACC/HFSA recommended pharmacologic therapies including target doses for patients with heart failure with reduced ejection fraction (HFrEF)
- Prescribe a guideline directed medical therapy to include specific medications and doses to a patient with HFrEF
- Recommend a target or goal blood pressure for a specific patient with hypertension based upon the current guidelines/data
- Recommend an evidence-based, cost effective antihypertensive medication regimen to a patient with hypertension
Speaker(s)/Author(s)
C. Wayne Weart, PharmD, FASHP, FAPhA
|
Activity Number
0062-9999-19-107-L01-PCE Hours
- Interpret spirometry
- Adjust medication classes on the basis of both symptoms and exacerbation frequency
- Improve medication compliance in their patients by better understanding the definition of an exacerbation
- Determine when a CT scan is indicated for obstructive lung diseases
Speaker(s)/Author(s)
Charles Strange, MD
|
Activity Number
0062-9999-19-108-L01-PCE Hours
- Incorporate spirometry into the definition of asthma to improve the specificity of diagnosis
- Discuss with patients the removal of boxed warnings from some inhalers but not others regarding increased risk of asthma death
- Incorporate a checklist for patients who are poorly controlled on current asthma therapy
- Determine when to refer patients for biologic therapy for asthma
Speaker(s)/Author(s)
Charles Strange, MD
|
Activity Number
0062-9999-19-109-L01-PCE Hours
- Identify patients who need osteoporosis screening
- Determine how long patients should continue bisphosphonates or other treatments
- Reduce a patient's risk of fracture in both primary and secondary prevention
Speaker(s)/Author(s)
Scott Bragg, PharmD, BCPS
|
Activity Number
0062-9999-19-110-L01-PCE Hours
- Discuss the history of cardiovascular outcomes trials (CVOT) for diabetes medications
- Compare the design and results of CVOT for DPP-4 inhibitors, thiazolidinediones, SGLT2 inhibitors, and GLP-1 receptor agonists
- Describe the role of CVOT in the 2019 ADA treatment algorithm
Speaker(s)/Author(s)
Morgan Adams, PharmD, BCACP
|
Activity Number
0062-9999-19-111-L01-PCE Hours
- Discuss the FDA Warnings and label changes that relate to medication safety and how this information should be applied in the selection and monitoring of evidence-based pharmacotherapy to achieve better patient related outcome
- Describe the 2019 updated ACIP/CDC Immunization recommendations and new FDA approved vaccines
- Describe the current information concerning newly FDA approved medications (pharmacology, pharmacokinetics, efficacy and safety data, drug interactions, dosing, monitoring and cost) in the selection of evidence-based pharmacotherapy
Speaker(s)/Author(s)
C. Wayne Weart, PharmD, FASHP, FAPhA
|